A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

NCT04041284 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

353

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine
Major Depressive Disorder

Interventions

DRUG: Fremanezumab
DRUG: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.